1-9 of 9
Jason M Foulks
Close
Sort by
Journal Articles

ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

Vladimir Riabov, Qingyu Xu, Nanni Schmitt, Alexander Streuer, Guo Ge, Johann-Christoph Jann, Alina Wein, Eva Altrock, Felicitas Rapp, Verena Nowak, Nadine Weimer, Julia Obländer, Iris Palme, Melda Göl, Mark Wunderlich, Ahmed Jawhar, Ali Darwich, Patrick Wuchter, Christel Weiss, Jason M Foulks, Daniel T. Starczynowski, Feng-Chun Yang, Georgia Metzgeroth, Laurenz Steiner, Wolf-Karsten Hofmann, Daniel Nowak, Mohamad Jawhar
Journal: Blood
Blood (2022) 140 (Supplement 1): 9749–9750.
https://doi.org/10.1182/blood-2022-165298
Published: 2022
Journal Articles

Activin-like Kinase 2 (ALK2/ACVR1) Is a Resistance Factor and Therapeutic Vulnerability to FLT3 Inhibition in Acute Myeloid Leukemia

Anudishi Tyagi, Stanley Ly, Bin Yuan, Fouad El-Dana, Vivek Anand, Appalaraju Jaggupilli, Gautam Borthakur, Jason M Foulks, Steven L. Warner, Venkata Lokesh Battula
Journal: Blood
Blood (2022) 140 (Supplement 1): 3052–3053.
https://doi.org/10.1182/blood-2022-167580
Published: 2022
Journal Articles

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal
Journal: Blood
Blood (2022) 140 (Supplement 1): 594–595.
https://doi.org/10.1182/blood-2022-159086
Published: 2022
Journal Articles

TP-0184, a Novel FLT3-ALK2 Dual Inhibitor, Targets Amino Acid Transport and Biosynthesis in AML Cells and Sensitizes AML Cells to Chemotherapy and BCL2 Inhibition

Anudishi Tyagi, Stanley Ly, Bin Yuan, Fouad El-Dana, Appalaraju Jaggupilli, Jason M Foulks, Steven L. Warner, Venkata Lokesh Battula
Journal: Blood
Blood (2021) 138 (Supplement 1): 376.
https://doi.org/10.1182/blood-2021-151251
Published: 2021
Journal Articles

Preclinical Assessment of Alvocidib in Combination with 5-Azacytidine in High-Risk Myelodysplastic Syndromes

Vladimir Riabov, Qingyu Xu, Nanni Schmitt, Alexander Streuer, Johann-Christoph Jann, Alina Wein, Eva Altrock, Arwin Mehralivand, Verena Nowak, Nadine Weimer, Julia Obländer, Iris Palme, Mohamad Jawhar, Christel Weiss, Georgia Metzgeroth, Jason M Foulks, Wolf-Karsten Hofmann, Daniel Nowak
Journal: Blood
Blood (2021) 138 (Supplement 1): 4649.
https://doi.org/10.1182/blood-2021-150778
Published: 2021
Journal Articles

Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models

Reona Sakemura, MDPhD, Michelle J. Cox, Elizabeth L. Siegler, PhD, Erin E. Tapper, Wendy K. Nevala, Mehrdad Hefazi, MD, Claudia Manriquez Roman, Kendall J. Schick, Ismail Can, Evandro D. Bezerra, MD, Lionel Kankeu Fonkoua, MD, Paulina Horvei, MD, Michael W. Ruff, MD, Lars Mouritsen, Jason M. Foulks, PhD, Steven L. Warner, PhD, Wei Ding, MD PhD, Susan L. Slager, PhD, Sameer A. Parikh, MD, Neil E. Kay, MD, Saad S. Kenderian, MB, ChB
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-142159
Published: 2020
Journal Articles

Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies

Reona Sakemura, MD PhD, Nan Yang, MD, Michelle J. Cox, Sutapa Sinha, PhD, Mehrdad Hefazi, MD, Michael J. Hansen, Kendall J. Schick, Cynthia L. Forsman, PhD, Justin C. Boysen, Renee C Tschumper, Elizabeth Juarez Diaz, BS, Lars Mouritsen, Jason M Foulks, PhD, Steven L. Warner, PhD, Sameer A. Parikh, MD, Wei Ding, MD PhD, Neil E. Kay, MD, Saad S. Kenderian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 728.
https://doi.org/10.1182/blood-2018-99-112209
Published: 2018
Journal Articles

The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma

Ethika Tyagi, PhD, Clifford Whatcott, PhD, Jason M Foulks, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3269.
https://doi.org/10.1182/blood-2018-99-120047
Published: 2018
Journal Articles

PAF-acetylhydrolase expressed during megakaryocyte differentiation inactivates PAF-like lipids

Jason M. Foulks, Gopal K. Marathe, Noemi Michetti, Diana M. Stafforini, Guy A. Zimmerman, Thomas M. McIntyre, Andrew S. Weyrich
Journal: Blood
Blood (2009) 113 (26): 6699–6706.
https://doi.org/10.1182/blood-2008-11-186312
Published: 2009
Includes: Supplemental data